Across TCGA pan-cancer cohorts, CCDC9B Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CCDC9B data layer compared with 25 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in lung squamous cell carcinoma (LUSC), where higher CCDC9B Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC9B expression acts as an unfavorable survival marker.
LUSC, SKCM, and PRAD are the cancer types where CCDC9B Mutation most reproducibly stratifies survival.
Mutation survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.